Connect with us
2027 health insurance premiums rise after expired ACA credits, a closed Medicare drug shield, and GLP-1 costs, with workers facing higher deductibles.
Zanvastro is the first Alexander disease drug, with an all-ages FDA label from a 54-person walking trial and a $285,000 quarterly dose.
A UK commission wants 44 new NHS AI rules, including learner plates and a right to know, while GP scribes already sit outside device law.
Gulf Vibrio vulnificus cases are rising through seawater wounds, while raw oysters still kill at a far higher rate in people with liver disease.
Medical groups posted 2026-27 flu, COVID-19 and RSV advice, but pharmacies, state boards and FDA labels still decide who can get vaccinated.
Rasonque lists at $39,800 a month after FDA approval, yet Medicare’s $2,100 Part D cap can close a patient’s share after one fill.
Congo’s Bundibugyo Ebola outbreak has killed 3,007 people, and the only licensed shot now going into arms is still a Zaire vaccine WHO will not endorse...
Medicare's GLP-1 Bridge sells Wegovy and Zepbound for $50, then routes sleep apnea and diabetes patients back to Part D copays of hundreds of dollars.
The 2026 heart attack definition recodes SCAD and spasm as primary attacks and requires sex-specific troponin cutoffs.
Hospital lobbyists want Medicaid cuts rolled back, yet the rural fund caps hospital care pay at 15 percent before 2027 work rules hit.
